Feb 9, 2022 | Innovation, News, Peptides
Secrets of an important byproduct revealed At Bachem, technological leadership and strong innovation have been the cornerstones of our success since the very beginning of our company. We strive for technology and highest quality of our products. Investing in research...
Dec 1, 2021 | News, Peptides, Trends
Corona Virus disease 2019 (COVID-19) affects us all, either directly with an infection or indirectly, through the impact other people’s infections have upon us. Severe Acute Respiratory Syndrome Coronaviruses 2 (SARS-CoV-2) enter our cells via the external part of the...
Nov 11, 2021 | Featured news, News, Oligonucleotides, Peptides, Press
Bachem lays foundations for company’s largest production building on Swiss National Future Day World’s most modern production building for peptides and oligonucleotides to be built in Bubendorf Strengthening of the Bubendorf site as a leading center of...
Oct 4, 2021 | CMC development, Knowledge, News, Peptides
A peptide is a chain of amino acids, which are used as building blocks. More commonly, peptides are short proteins with varying lengths from 2 amino acids to 100 amino acids. Peptides can be found in nature and can perform biological functions such as acting as...
Sep 24, 2021 | Innovation, Leadership, News, Peptides, Trends
Companies that do not just care about their financial bottom line but also about the environment and society are more successful. Today, this fact has reached more than just investors. But investor attention is not the only reason why Bachem is committed to corporate...
Sep 15, 2021 | News, Peptides, Trends
Liraglutide, a so-called glucagon like peptide-1 (GLP-1) receptor agonist, is used for the treatment of Type 2 diabetes mellitus (T2D) and obesity. Marketed as Victoza® and Saxenda® by Novo Nordisk, the drug is a peptide analog of the human GLP-1, a hormone with many...
